Business

Inhaled liposomal ciprofloxacin developer Aradigm Corporation announced that it has filed for bankruptcy under Chapter 11 of the US Bankruptcy Code and plans to sell all of its assets. The company said that "Aradigm remains confident in the efficacy, safety and quality of Apulmiq (US)/Linhaliq (EMA). We are committed to continue working toward the approval of … [Read more...] about Aradigm files for bankruptcy, plans to sell all assets

Glenmark Pharmaceuticals has announced that it plans to spin off a US-based company for development of innovative drugs, including GRC 39815, a retinoid-related orphan receptor gamma t (RORγt) inhibitor in pre-clinical development as a potential inhaled treatment for COPD. The new US-based company is expected to employ over 400 people, and all employees, assets, … [Read more...] about Glenmark inhaled RORγt inhibitor to be developed by US spin-off

The US Patent and Trademark Office (USPTO) has provided VistaGen a notice of allowance regarding a patent covering the use of its PH10 nasal spray for the treatment of depression, the company said. VistaGen announced that it had licensed PH10, a neurosteroid nasal spray, from Pherin Pharmaceuticals in October 2018. PH10 is currently in Phase 2 development for the … [Read more...] about VistaGen gets notice of allowance for patent covering PH10 nasal spray for the treatment of depression

Both GSK and Mylan have announced the availability of generic versions of GSK's Advair Diskus fluticasone propionate/salmeterol DPI in the US. GSK made a statement regarding its authorized generic on February 8, 2019, and Mylan has responded by announcing the US launch of the Wixela Inhub fluticasone propionate/salmeterol DPI, which was recently approved by … [Read more...] about GSK, Mylan launch generic versions of Advair Diskus in US

Pulmatrix announced that it has received five new patents covering PUR1800 and PUR5700, which are inhaled narrow spectrum kinase inhibitors that Pulmatrix licensed from Janssen subsidiary RespiVert in June 2017. The new patents include two US patents (Nos. 9,884,845 B2 and 10,045,980 B2) and two European patents (Nos. 3105222 B1 and 3105223 B1) covering RV-7031, … [Read more...] about Pulmatrix gets five new patents for DPI formulations

Avadel Specialty Pharmaceuticals, which marketed Noctiva desmopressin nasal spray in the US, has filed for Chapter 11 bankruptcy, parent company Avadel Pharmaceuticals announced. Less than a year after launching Noctiva in the US, Avadel said that it will no longer market the product. Noctiva was approved by the FDA in March 2017 for the treatment of nocturnal … [Read more...] about Avadel Pharmaceuticals drops Noctiva nasal spray

Glenmark Pharmaceuticals announced that it has agreed to a licensing deal giving Grandpharma exclusive rights to commercialize Ryaltris olopatadine hydrochloride/mometasone furoate nasal spray in China. The company recently announced that Yuhan had acquired South Korean rights to Ryaltris in South Korea. In July 2018, Glenmark said that it had reached an agreement … [Read more...] about Grandpharma acquires Chinese rights to Ryaltris nasal spray